Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis

Does low does naltrexone (LDN) improve quality of life in PwMS?

A study in 80 PwMS was performed to evaluate the effect of 8 weeks of treatment with LDN (4.5mg taken at night). Although LDN was associated with significant improvement in some mental health quality of life measures, the trial was too small to draw definitive conclusions.

Interpretation: this study was too small to be definitive. However, it provides further support for a large definitive study of LDN in MS. Unfortunately, the current "Big Pharma" business model does not support investigating drugs that are off patent. May be "Big Pharma" will now try and develop a follow-on me-to drug to test in PwMS.

Cree et al. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug;68(2):145-50.